Addenbrooke specialist welcomes first of ‘new wave’ of NHS treatments for endometrial cancer

The first immunotherapy treatment to help treat women with advanced endometrial cancer will be made available on the NHS in England.

A type of treatment called Dostarlimab will become the first immunotherapy to be available on the NHS in England to help treat women with advanced endometrial cancer through the Cancer Drugs Fund.

Dostarlimab, branded Jemperli, is used to treat an aggressive form of endometrial cancer that has progressed despite chemotherapy.

Read more: Health news

Endometrial cancer is cancer of the womb lining and it is the most commonly diagnosed gynecological cancer in the UK and the seventh most common cause of cancer death in the UK.



By signing up to the CambridgeshireLive newsletter you will receive our daily news email.

It couldn’t be simpler and it takes seconds – simply click here, enter your email address and follow the instructions.

You can also enter your address at the top of this page in the box below the image on most desktop and mobile platforms.

Changed your mind? There is an “unsubscribe” button at the bottom of every newsletter we send.

The prognosis for patients diagnosed with advanced or recurrent endometrial cancer is extremely poor with a reported average survival of less than 12 months, with only 15% of women diagnosed with advanced disease surviving for 5 years or more.

Prior to the decision to approve Dostarlimab for the treatment of endometrial cancer, there was no standard of care for patients with advanced or recurrent endometrial cancer once they have progressed during or after platinum-containing chemotherapy.

But just on Tuesday, February 8, GSK welcomed the decision by the National Institute for Health and Care Excellence (NICE) to release the final review decision recommending the use of Dostarlimab.

This study was conducted through the Cancer Drugs Fund (CDF) as a treatment option for patients with a common and aggressive form of advanced endometrial cancer.

The decision will make Dostarlimab available through the CDF for adult patients with mismatch repair deficiency, known as dMMR/MSI-H, which is believed to contribute to the rapid spread of this type of cancer, making it difficult to treat with standard chemotherapy.

As well as being available for people with recurrent or advanced endometrial cancer that has progressed during or after previous treatment with a type of chemotherapy.

There are around 7,700 new cases of endometrial cancer each year in the UK, and of these, over 170 women are estimated to be eligible for treatment with Dostarlimab.

Approval of Dostarlimab treatment will help increase their chances of stabilizing or slowing the progression of their disease.

Speaking to medical oncologist Dr Ang from Addenbrooke’s Hospital about the new treatment, he said: “I personally welcome the news and ‘it’s very exciting’.

Also adding: “This is part of a new wave of treatments that is coming”.

Dr Ang also said: “Historically this was really an area of ​​unmet clinical need, so the approval of this particular drug in this setting is welcome.

“I think it’s a long time coming and it’s not unexpected for us. We were really hoping that NICE would give us their blessing to use these compounds extravagantly for the appropriate patients.”

Dr Ang also highlighted how common this type of cancer is and said: ‘It is the most common type of uterine cancer and the most commonly diagnosed type of gynecological cancer in the UK and around the world. the world.



If you’re looking for a way to keep up to date with the latest news from across Cambridgeshire, the CambridgeshireLive app has you covered.

Available for free on iOS and Android devices, the clean and tidy interface is the easiest way to follow our news.

The CambridgeshireLive team are committed to bringing our readers the latest breaking news, in-depth features and exclusive content from across the county.

Once installed, you can even select the area you live in to receive dedicated notifications whenever we post a story relevant to you.

If you have an iOS device, you can download it from the Online App Store by clicking here.

If you have an Android device, you can find the app on the Google Play Store here.

“It is also a very common cause of death from cancer in the UK.

“There’s not a lot of media coverage and not much representation at all.”

Dr. Ang also added that the treatment Dostarlimab will now be available, which he hopes will help raise awareness about endometrial cancer.

Dr Susana Banerjee, Consultant Medical Oncologist, The Royal Marsden NHS Foundation Trust, said: “To date, beyond chemotherapy, treatment options for women with advanced and recurrent endometrial cancer in England are limited.

“NICE’s decision changes that, offering patients whose cancer has a specific abnormality called MSI-H deficiency or MMR the opportunity to access immunotherapy with Dostarlimab. NICE’s decision is a step forward in the improving outcomes for women with endometrial cancer by providing treatment.”

Want more news straight to your inbox? Sign up for our newsletter here.

Comments are closed.